Grant: Operating Grant: Future Leaders in Canadian Brain Research Program
University of Toronto
$100,000.00
Epitranscriptomic regulation of sleep, neurodegeneration, and longevity
FY 2024-25
Summary
Neurodegenerative diseases, such as Alzheimer's, exhibit intricate links to sleep disturbances, aging, and cognitive decline. Sleep abnormalities often precede clinical symptoms in neurodegenerative disorders, with disrupted sleep patterns emerging as an early and common feature. As individuals age, the risk of developing neurodegenerative diseases increases, and the bidirectional relationship between sleep and cognitive decline becomes more apparent. Sleep disruptions, including fragmented sleep and alterations in sleep architecture, are not only symptomatic but may also contribute to the acceleration of cognitive decline. The underlying mechanisms intertwining these phenomena involve the intricate interplay between neuronal damage, protein aggregation, and disruptions in circadian rhythms. Understanding these multifaceted relationships is crucial for developing comprehensive strategies aimed at both preventing and treating these challenging conditions. This proposal focuses on understanding the role of a novel mechanism of gene regulation, the epitranscriptomic mark N6-methyladenosine (m6A), in regulating sleep and aging-related cognitive decline in Drosophila. m6A is a prevalent and conserved chemical alteration in eukaryotic mRNA which has recently been shown to affect the regulation of the circadian clock and molecular processes associated with learning and memory in flies and mammals. Preliminary data from our lab shows that misregulation of m6A results in fragmented sleep and accumulation of protein aggregates in the brain, hallmarks of neurodegenerative disease. Additionally, our data shows that genetic and pharmacological manipulation of m6A levels has bi-directional effects on lifespan, with severe inhibition of m6A drastically reducing lifespan, but moderate inhibition having beneficial effects. Building on these preliminary findings, this proposal has three aims: 1- Elucidate the neuronal pathways in which m6A acts to regulate neuropathological phenotypes; 2- Investigate m6A dynamics in the aging brain and the mechanistic links to cognitive decline; and 3 - Test whether targeted and/or timed manipulation of m6A levels can improve neurodegenerative pathophysiology in an Alzheimer’s disease model.
Department
Program
Operating Grant: Future Leaders in Canadian Brain Research Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
532137
Name
Anreiter Ina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Brain Canada Foundation (Montreal, Québec)
Prcname2
Special Cases
Projecttitle
Epitranscriptomic regulation of sleep, neurodegeneration, and longevity
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant: Future Leaders in Canadian Brain Research Program
Keyworddelim
Cognitive Decline; Neurodegenerative Diseases; Sleep
Abstract
Neurodegenerative diseases, such as Alzheimer's, exhibit intricate links to sleep disturbances, aging, and cognitive decline. Sleep abnormalities often precede clinical symptoms in neurodegenerative disorders, with disrupted sleep patterns emerging as an early and common feature. As individuals age, the risk of developing neurodegenerative diseases increases, and the bidirectional relationship between sleep and cognitive decline becomes more apparent. Sleep disruptions, including fragmented sleep and alterations in sleep architecture, are not only symptomatic but may also contribute to the acceleration of cognitive decline. The underlying mechanisms intertwining these phenomena involve the intricate interplay between neuronal damage, protein aggregation, and disruptions in circadian rhythms. Understanding these multifaceted relationships is crucial for developing comprehensive strategies aimed at both preventing and treating these challenging conditions. This proposal focuses on understanding the role of a novel mechanism of gene regulation, the epitranscriptomic mark N6-methyladenosine (m6A), in regulating sleep and aging-related cognitive decline in Drosophila. m6A is a prevalent and conserved chemical alteration in eukaryotic mRNA which has recently been shown to affect the regulation of the circadian clock and molecular processes associated with learning and memory in flies and mammals. Preliminary data from our lab shows that misregulation of m6A results in fragmented sleep and accumulation of protein aggregates in the brain, hallmarks of neurodegenerative disease. Additionally, our data shows that genetic and pharmacological manipulation of m6A levels has bi-directional effects on lifespan, with severe inhibition of m6A drastically reducing lifespan, but moderate inhibition having beneficial effects. Building on these preliminary findings, this proposal has three aims: 1- Elucidate the neuronal pathways in which m6A acts to regulate neuropathological phenotypes; 2- Investigate m6A dynamics in the aging brain and the mechanistic links to cognitive decline; and 3 - Test whether targeted and/or timed manipulation of m6A levels can improve neurodegenerative pathophysiology in an Alzheimer’s disease model.
Competitiondate
202503
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Anreiter, Ina
Approvedterm
2 ans 0 mois
Cihrcontribution2
IA~ $20,833~ $0~MI #2~ $79,167~ $0~